Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: AVZO-021
Drug: Palbociclib
Drug: Fulvestrant
Drug: Letrozole
Drug: Ribociclib
Drug: Abemaciclib
Drug: Carboplatin

First Posted Date: 2023-05-19

Last Posted Date: 2024-05-30

Lead Sponsor: Avenzo Therapeutics, Inc.

Target Recruit Count: 430

Registration Number: NCT05867251

Locations: 🇺🇸
NEXT Virginia, Fairfax, Virginia, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, Pennsylvania, United States

and more 3 locations

Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers

Phase 2

Recruiting

Conditions: Estrogen-receptor-low Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Carboplatin
Drug: Tocilizumab

First Posted Date: 2023-05-06

Last Posted Date: 2024-06-07

Lead Sponsor: Kathy Miller

Target Recruit Count: 168

Registration Number: NCT05846789

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana, United States
🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

and more 1 locations

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: lorlatinib
Drug: crizotinib
Drug: brigatinib
Drug: ceritinib
Drug: alectinib
Drug: atezolizumab
Drug: bevacizumab
Drug: paclitaxel
Drug: carboplatin
Drug: docetaxel
Drug: erlotinib
Drug: gefitinib
Drug: afatinib
Drug: dacomitinib
Drug: osimertinib
Drug: pembrolizumab
Drug: nivolumab
Drug: entrectinib

First Posted Date: 2023-04-28

Last Posted Date: 2023-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 20605

Registration Number: NCT05834348

Locations: 🇳🇴
Pfizer Norway, Oslo, Norway

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)

Phase 2

Recruiting

Conditions: Untreated Advanced or Recurrent Thymic Carcinomas

Interventions: Drug: MK-3475
Drug: Lenvatinib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2023-04-27

Last Posted Date: 2023-10-23

Lead Sponsor: National Cancer Center, Japan

Target Recruit Count: 35

Registration Number: NCT05832827

Locations: 🇯🇵
National Cancer Center Hospital, Chuo, Tokyo, Japan

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent Grade 3b Follicular Lymphoma
Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Etoposide
Drug: Ifosfamide
Drug: Lenalidomide
Procedure: Positron Emission Tomography
Biological: Tafasitamab

First Posted Date: 2023-04-20

Last Posted Date: 2024-11-15

Lead Sponsor: David Bond, MD

Target Recruit Count: 37

Registration Number: NCT05821088

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Dostarlimab
Drug: Cisplatin

First Posted Date: 2023-04-19

Last Posted Date: 2024-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT05819892

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: SKB264
Drug: Osimertinib
Drug: Pembrolizumab
Drug: Carboplatin

First Posted Date: 2023-04-18

Last Posted Date: 2024-07-31

Lead Sponsor: Klus Pharma Inc.

Target Recruit Count: 278

Registration Number: NCT05816252

Locations: 🇦🇺
St Vincent's Hospital - Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

and more 63 locations

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase 1

Recruiting

Conditions: Small Cell Lung Cancer Recurrent

Interventions: Drug: Debio 0123
Drug: Etoposide
Drug: Carboplatin

First Posted Date: 2023-04-18

Last Posted Date: 2024-12-20

Lead Sponsor: Debiopharm International SA

Target Recruit Count: 78

Registration Number: NCT05815160

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

and more 11 locations